Sutent (sunitinib malate, formerly SU-11248)

 
Sunitinib (Sutent) is a tyrosine kinase inhibitor that has anti-cancer and anti-angiogenesis effects. It was previously known as SU-11248, and its chemical name is sunitinib malate.  Sutent is manufactured by Pfizer.

Pfizer has a website for patients taking Sutent at www.sutent.com where patients can find helpful information and videos, seek financial assistance with the cost of Sutent, or contact the Sutent Patient Call Center to speak with a nurse about Sutent treatment.  You can reach the Sutent Patient Call Center Monday through Friday, 8 AM to 7 PM CT at 1-877-5-SUTENT (1-877-578-8368).

Sutent was approved by the FDA for treatment of imatinib-resistant and imatinib-intolerant gastrointestinal stromal tumor (GIST) and for renal cell carcinoma on January 26, 2006. Link here to the FDA approval notice. There is also a patient information sheet at the FDA site.

Patients in countries where Sutent has not yet been approved can obtain access to the drug through a clinical trial process.  Access this trial link and look for a site in the country of interest to you.  Currently sites are open in India and Taiwan.  You may also call the international phone number for Emerging Med trial matching service at  646-277-4065.

Our information about sunitinib (Sutent) for GIST is divided among these pages (click to link).

Sunitinib (Sutent) Basics for GIST

Sunitinib (Sutent) Treatment for GIST

Sunitinib (Sutent) Side Effects and Management

 

 

Papers about Sutent

 

If you would like to read abstracts of medical papers concerning Sutent, click here to display PubMed listings for recent papers.